What is Incyte's JAKAVI — royalties payable on net sales?

Incyte (INCY) reported JAKAVI — royalties payable on net sales of $96.6M in Q3 2023.

What does JAKAVI — royalties payable on net sales mean?

The total dollar amount of royalty payments owed to a partner based on product sales.

How do you interpret JAKAVI — royalties payable on net sales?

An increase in royalties payable generally correlates with higher product sales, but a disproportionate rise relative to revenue could indicate unfavorable contract terms.

How does JAKAVI — royalties payable on net sales compare across companies?

Common for companies that in-license drug candidates; peers report these as cost of goods sold or operating expenses depending on accounting treatment.

Incyte INCY JAKAVI — Royalties payable on net sales

Discontinued — last reported Q3 '23

Similar metrics at other companies

NBIXRoyalty — Total revenues

$6.7M+123%

BIIBRoyalty and other revenue — Total Revenue

$9.7M-11.8%

IONSPelacarsen Active Pharmaceutical Ingredient — Royalty Percentage Received On Net Sales Of Medicine

5%0.0pp

INSMARIKAYCE Global Net Sales — Royalty percentage

4.5%—

ROIVLicense, milestone and other revenue — Revenue, net

$0-100%

IONSPelacarsen Active Pharmaceutical Ingredient — Percentage Of Royalty Payments Paid On Annual Sales Of Medicine

25%0.0pp

Other financials

Income statement

See full

Revenue$1.3B+20.9%

Gross profit$1.2B+19.2%

Operating income$301.1M+46.8%

Net income$303.3M+91.7%

EPS (diluted)$1.47+83.7%

Balance sheet

See full

Cash & equivalents$3.5B+78.2%

Total debt$39.4M-8.6%

Total equity$5.6B+53.3%

Total assets$7.3B+27.7%

Cash flow

See full

Operating cash flow$369.4M+38.8%

CapEx$1.6M-43.5%

Free cash flow$367.7M+39.7%

Valuation

See full

Market cap$19.62B+59.9%

Enterprise value$16.2B+55.9%

P/E13.7×-564×

P/S3.7×+0.9×

Profitability

See full

Gross margin92.5%-0.2pp

Operating margin30%+26.1pp

Net margin26.7%+26.2pp

FCF margin28.2%+19.7pp

Returns & leverage

See full

Return on equity30.8%+30.4pp

Debt / equity0×0.0×

Current ratio3.7×+1.6×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInRoyaltiesPayable.

The official record: Incyte’s 10-Q, filed October 31, 2023, on SEC EDGAR. View the filing →

Ask your AI about Incyte's jakavi — royalties payable on net sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Incyte's JAKAVI — royalties payable on net sales?: Incyte (INCY) reported JAKAVI — royalties payable on net sales of $96.6M in Q3 2023.
What does JAKAVI — royalties payable on net sales mean?: The total dollar amount of royalty payments owed to a partner based on product sales.
How do you interpret JAKAVI — royalties payable on net sales?: An increase in royalties payable generally correlates with higher product sales, but a disproportionate rise relative to revenue could indicate unfavorable contract terms.
How does JAKAVI — royalties payable on net sales compare across companies?: Common for companies that in-license drug candidates; peers report these as cost of goods sold or operating expenses depending on accounting treatment.